Sav1 Loss Induces Senescence and Stat3 Activation Coinciding with Tubulointerstitial Fibrosis
Janet Y Leung1,2, Harper L Wilson3, Kristin J Voltzke3,4
1Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA janet_leung@med.unc.edu wykim@med.unc.edu.
Abstract:
Tubulointerstitial fibrosis (TIF) is recognized as a final phenotypic manifestation in the transition from chronic kidney disease (CKD) to end-stage renal disease (ESRD). Here we show that conditional inactivation of Sav1 in the mouse renal epithelium resulted in upregulated expression of profibrotic genes and TIF. Loss of Sav1 induced Stat3 activation and a senescence-associated secretory phenotype (SASP) that coincided with the development of tubulointerstitial fibrosis. Treatment of mice with the YAP inhibitor verteporfin (VP) inhibited activation of genes associated with senescence, SASPs, and activation of Stat3 as well as impeded the development of fibrosis. Collectively, our studies offer novel insights into molecular events that are linked to fibrosis development from Sav1 loss and implicate VP as a potential pharmacological inhibitor to treat patients at risk for developing CKD and TIF.
Insights
Loss of Sav1 in mouse kidneys causes tubulointerstitial fibrosis (TIF) by activating Stat3 and senescence. YAP inhibitor verteporfin (VP) blocked fibrosis, suggesting VP as a potential treatment for chronic kidney disease (CKD).
Area of Science:
- Nephrology
- Molecular Biology
- Pathology
Background:
- Tubulointerstitial fibrosis (TIF) is a key factor in chronic kidney disease (CKD) progression to end-stage renal disease (ESRD).
- The molecular mechanisms driving TIF are not fully understood, highlighting the need for further research into fibrotic pathways.
Purpose of the Study:
- To investigate the role of Sav1 in renal tubulointerstitial fibrosis.
- To explore the potential of YAP inhibition as a therapeutic strategy for TIF.
Main Methods:
- Conditional inactivation of the Sav1 gene in mouse renal epithelium.
- Analysis of gene expression, Stat3 activation, and senescence-associated secretory phenotype (SASP).
- Treatment with the YAP inhibitor verteporfin (VP) to assess its effects on fibrosis.
Main Results:
- Conditional Sav1 inactivation in renal epithelium upregulated profibrotic genes and induced TIF.
- Loss of Sav1 activated Stat3 and promoted a SASP, correlating with fibrosis development.
- Verteporfin treatment inhibited senescence-related gene activation, Stat3, and SASP, thereby impeding fibrosis.
Conclusions:
- Sav1 deficiency in renal epithelium drives TIF through Stat3 activation and SASP.
- YAP inhibition with verteporfin shows promise in preventing or treating TIF.
- These findings offer new insights into fibrosis mechanisms and identify VP as a potential therapeutic agent for CKD and TIF.
Related Concept Videos
The JAK-STAT Signaling Pathway
TGF - β Signaling Pathway
Replicative Cell Senescence
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...


